"The public praise list activity of listed companies" has blossomed in Chengdu, and many seed pharmaceutical enterprises stand out!

[industry trends of China Pharmaceutical network] on November 16, the 2018 eighth public praise list of Chinese listed companies was held in Chengdu Through strict screening, all awards are settled In the field of medicine, many pharmaceutical companies are on the list Among them, Yunnan Baiyao, Bubu pharmaceutical and Lizhu group won the good board of directors Award; Yan'an Bikang, Xianju pharmaceutical, Shanghai pharmaceutical, tisley, jiankangyuan and Tianyu Co., Ltd won the growth listed company in the big health industry; Kanghong pharmaceutical won the Board Secretary award of the good listed company; Kanghong pharmaceutical and Kangzhi pharmaceutical won the Social Responsibility Award Kanghong Pharmaceutical Co., Ltd won two laurels, i.e Board Secretary award and Social Responsibility Award, and became one of the big winners of the day According to the third quarter report of 2018 disclosed by Kanghong pharmaceutical, the company's asset scale is close to 5 billion yuan at present It is good business development that supports the scale of the company In the first three quarters of this year, Kanghong pharmaceutical industry achieved revenue of 2.18 billion yuan, an increase of 3.95% year-on-year; the net profit attributable to shareholders of the company was 500 million yuan, an increase of 21.84% year-on-year With its performance, mature corporate governance and sound business strategy, step Pharma has won the "2018 eighth China listed company reputation top listed company board Award" Step pharmaceutical is committed to the modernization of traditional Chinese medicine, giving full play to the important role of traditional Chinese medicine in the field of cardiovascular and cerebrovascular diseases, forming a three-dimensional product pattern based on the market of cardiovascular and cerebrovascular diseases, covering the traditional advantages of Chinese patent medicine, focusing on major diseases and cultivating large varieties According to its third quarter report, from January to September 2018, the company achieved an operating revenue of 9.286 billion yuan Influenced by a series of policies and regulations such as further deepening the reform of the medical and health system and carrying out in-depth supply side reform of the pharmaceutical industry, the pharmaceutical industry shrank in an all-round way, and the company's total operating revenue decreased compared with the same period last year, but was basically the same; The net profit attributable to the parent company was 1.215 billion yuan, up 7.57% year on year Pu Xiaoping, vice president and Secretary of board of directors of step pharmaceutical, said that in the future, the board of directors will guard against arrogance and impetuosity, and continue to accurately grasp the direction of the company's navigation while getting wide attention and recognition from investors, so as to achieve steady growth in performance and steady progress in business strategy Yan'an Bikang Yan'an Bikang won the title of "growth listed company of large health industry" by virtue of steady growth performance, continuous improvement of comprehensive strength and follow-up strong development potential In the third quarter of 2018, the company achieved an operating revenue of 1.903 billion yuan, an increase of 21.95% year-on-year; the net profit attributable to shareholders of the listed company was 172 million yuan, an increase of 4.25% year-on-year, with stable growth in both revenue and profit In the third quarter, the net operating cash flow of the company was 234 million yuan, an increase of 87.30% year on year, with good profit quality Bikang group said that in the future, it will continue to adhere to the strategic policy, adhere to the enterprise concept of "must take good medicine, healthy world", and the brand concept of "Bikang pharmaceutical, only positive way"; make full use of the capital platform, integrate the whole industry chain of the pharmaceutical industry, build Bikang large health industry platform, and set a new benchmark for the Chinese pharmaceutical health industry In order to achieve the strategic goal of "building Bikang pharmaceutical into a brand of Chinese plant pharmaceutical enterprise" and an internationally famous brand.